268 related articles for article (PubMed ID: 20469672)
1. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
Federico A; Trappoliere M; Loguercio C
Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.
Wong VW; Hui AY; Tsang SW; Chan JL; Wong GL; Chan AW; So WY; Cheng AY; Tong PC; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2006 Oct; 24(8):1215-22. PubMed ID: 17014580
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
6. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
7. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.
Yasutake K; Nakamuta M; Shima Y; Ohyama A; Masuda K; Haruta N; Fujino T; Aoyagi Y; Fukuizumi K; Yoshimoto T; Takemoto R; Miyahara T; Harada N; Hayata F; Nakashima M; Enjoji M
Scand J Gastroenterol; 2009; 44(4):471-7. PubMed ID: 19058085
[TBL] [Abstract][Full Text] [Related]
8. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
Yki-Järvinen H
Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
Roden M
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
[TBL] [Abstract][Full Text] [Related]
11. [Advisability of using probiotics in the treatment of atherogenic dyslipidemia].
Zvenigorodskaia LA; Cherkashova EA; Samsonova NG; Nilova TV; Sil'verstova SIu
Eksp Klin Gastroenterol; 2011; (2):37-43. PubMed ID: 21563361
[TBL] [Abstract][Full Text] [Related]
12. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic steatohepatitis in type 2 diabetes mellitus.
Gupte P; Amarapurkar D; Agal S; Baijal R; Kulshrestha P; Pramanik S; Patel N; Madan A; Amarapurkar A; Hafeezunnisa
J Gastroenterol Hepatol; 2004 Aug; 19(8):854-8. PubMed ID: 15242486
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.
Morita Y; Ueno T; Sasaki N; Tateishi Y; Nagata E; Kage M; Sata M
Hepatogastroenterology; 2005; 52(65):1338-43. PubMed ID: 16201069
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
16. [Nonalcoholic fatty liver disease and insulin resistance: clinical, biochemical, and morphological parallels].
Zvenigorodskaia LA; Drozdov VN; Egorova EG
Eksp Klin Gastroenterol; 2008; (3):25-30. PubMed ID: 19145879
[No Abstract] [Full Text] [Related]
17. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
18. Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect?
Safwat GM; Pisanò S; D'Amore E; Borioni G; Napolitano M; Kamal AA; Ballanti P; Botham KM; Bravo E
Nutrition; 2009; 25(11-12):1157-68. PubMed ID: 19592219
[TBL] [Abstract][Full Text] [Related]
19. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
Zheng LY; Pan JQ; Lv JH
Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
[TBL] [Abstract][Full Text] [Related]
20. [Atherogenic dyslipidaemia in type 2 diabetes].
Zozulińska D
Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S567-71. PubMed ID: 20527378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
